A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

摘要: A collaborative overview, using individual patient data, has been performed to compare idarubicin versus daunorubicin or other anthracyclines, when used with cytosine arabinoside as induction chemotherapy for newly diagnosed acute myeloid leukaemia. There were 1052 patients in five trials daunorubicin, 100 one trial doxorubicin, and 745 zorubicin. In the of early failures similar two treatments (20% v 18% daunorubicin; P = 0.4), but after day 40 later fewer (17% 29%; P < 0.0001). Therefore complete remission rates higher (62% 53%; P = 0.002). Among remitters, allocated relapsed (P = 0.008) slightly more died remission, leading a non-significant benefit (P = 0.07) disease-free survival. Overall survival these was significantly better than (13% 9% alive at 5 years; P = 0.03). trend (P = 0.006 rate) over decrease increasing age. no significant differences outcome small comparing large The regimens based on achieved, particular circumstances reviewed here, overall those daunorubicin.